Condition: Glioblastoma (GBM) · Newly Diagnosed Glioblastoma · GBM · Sponsor: Black Diamond Therapeutics, Inc.
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?
This description comes directly from the study's public registry record.
Black Diamond Therapeutics Clinical Trial Navigation Service · (866) 955-4397 · blackdiamondtx@careboxhealth.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham O'Neal Comprehensive Cancer Center | Birmingham, Alabama, United States | Recruiting |
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Johns Hopkins Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Johns Hopkins Sidney Kimmel Cancer Center - Baltimore | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Cancer- Detroit | Detroit, Michigan, United States | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07326566